Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Mounjaro has now become available on the NHS for patients in the UK, meaning doctors will have a lot more work on their ...

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

As Wegovy ushers in a new wave of weight-loss drugs to tackle India's growing obesity crisis, Dr. Rishma Pai sheds light on their use in obese women dealing with PCOS, infertility, and menopausal ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...